Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Total Debt (2018 - 2023)

Protagonist Therapeutics (PTGX) has disclosed Total Debt for 6 consecutive years, with $10000.0 as the latest value for Q2 2023.

  • Quarterly Total Debt fell 87.5% to $10000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $10000.0 through Jun 2023, down 87.5% year-over-year, with the annual reading at $69000.0 for FY2022, 92.32% down from the prior year.
  • Total Debt hit $10000.0 in Q2 2023 for Protagonist Therapeutics, down from $22000.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $11.4 million in Q2 2021 to a low of $10000.0 in Q2 2023.
  • Historically, Total Debt has averaged $1.8 million across 5 years, with a median of $1.0 million in 2019.
  • Biggest five-year swings in Total Debt: soared 1036.19% in 2021 and later plummeted 99.3% in 2022.
  • Year by year, Total Debt stood at $1.3 million in 2019, then skyrocketed by 116.48% to $2.7 million in 2020, then crashed by 67.09% to $899000.0 in 2021, then tumbled by 92.32% to $69000.0 in 2022, then crashed by 85.51% to $10000.0 in 2023.
  • Business Quant data shows Total Debt for PTGX at $10000.0 in Q2 2023, $22000.0 in Q1 2023, and $69000.0 in Q4 2022.